Table 3.

Sensitivity analyses: adjusted hazard ratios among U.S. patients with end-stage renal disease attributed to lupus nephritis, who received a transplant (1/1/00-9/30/11), from restricted cubic splines of time to transplant.

Time to transplant (months)	Hazard ratio (95% CI) for graft failure at median value in interval
	Adjusted for peak PRA (N=2442)	Adjusted for pre-ESRD care (2005+ only; N=1275)	Graft failures excluding deaths with functioning transplant* (N=4280)	Graft failures within 30 days excluded (N=4149)	Stratified by donor type:
					Living (N=1944)	Deceased (N=2336)
Overall
<3	1.00 (ref)	1.00 (ref)	1.00 (ref)	1.00 (ref)	1.00 (ref)	1.00 (ref)
3–12	1.10 (0.89–1.35)	1.56 (1.08–2.25)	1.26 (1.02–1.55)	1.25 (1.05–1.49)	1.19 (0.94–1.50)	1.12 (0.85–1.49)
12–24	1.12 (0.82–1.53)	1.79 (1.05–3.05)	1.37 (1.05–1.88)	1.37 (1.05–1.79)	1.46 (1.04–2.04)	1.05 (0.69–1.62)
24–36	1.03 (0.77–1.37)	1.25 (0.72–2.16)	1.16 (0.87–1.55)	1.20 (0.94–1.53)	1.76 (1.28–2.42)	0.76 (0.52–1.11)
>36	1.09 (0.81–1.47)	1.51 (0.77–2.98)	1.07 (0.79–1.45)	1.21 (0.94–1.57)	1.27 (0.87–1.86)	0.86 (0.59–1.26)
Black
<3	1.00 (ref)	1.00 (ref)	1.00 (ref)	1.00 (ref)	1.00 (ref)	1.00 (ref)
3–12	0.93 (0.65–1.33)	1.17 (0.68–2.00)	1.07 (0.76–1.51)	1.07 (0.79–1.45)	1.09 (0.73–1.64)	0.83 (0.52–1.33)
12–24	0.83 (0.48–1.42)	1.12 (0.51–2.43)	1.02 (0.61–1.72)	1.01 (0.64–1.60)	1.14 (0.63–2.08)	0.64 (0.31–1.34)
24–36	0.69 (0.42–1.13)	0.76 (0.35–1.64)	0.79 (0.49–1.27)	0.78 (0.51–1.18)	1.06 (0.61–1.83)	0.47 (0.24–0.91)
>36	0.68 (0.41–1.12)	0.67 (0.27–1.68)	0.67 (0.41–1.08)	0.74 (0.48–1.13)	0.70 (0.37–1.31)	0.49 (0.26–0.95)
White
<3	1.00 (ref)	1.00 (ref)	1.00 (ref)	1.00 (ref)	1.00 (ref)	1.00 (ref)
3–12	1.15 (0.83–1.61)	1.44 (0.72–2.85)	1.20 (0.84–1.71)	1.23 (0.93–1.63)	0.99 (0.69–1.42)	1.47 (0.94–2.30)
12–24	1.23 (0.77–1.98)	1.51 (0.58–3.96)	1.26 (0.76–2.10)	1.37 (0.92–2.06)	1.26 (0.76–2.10)	1.41 (0.74–2.72)
24–36	1.21 (0.78–1.89)	1.22 (0.38–3.97)	1.12 (0.69–1.81)	1.34 (0.92–1.97)	2.29 (1.43–3.66)	0.75 (0.41–1.36)
>36	1.97 (1.21–3.21)	11.0 (2.61–46.1)	1.83 (1.11–3.04)	1.98 (1.31–2.99)	1.88 (1.05–3.35)	1.66 (0.90–3.04)

CI, confidence interval; PRA, panel reactive antibody; ESRD, end-stage renal disease. Adjusted for age, race (overall model only; referent group=white), insurance at start of end-stage renal disease (referent group=Medicaid), hemoglobin at start of end-stage renal disease, and donor type (non-donor type-stratified models only; referent group=living donor). PRA: <20% (referent group), 20–80%, and ≥80%); pre-ESRD care: yes and no (=referent group).

^*Censoring 309/1239 graft failure events that were deaths with a functioning transplant.